douglas-pharma-and-uwa-join-hands-for-developing-new-cancer-therapies
Category: #health  By Dhananjay Punekar  Date: 2018-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

douglas-pharma-and-uwa-join-hands-for-developing-new-cancer-therapies

Douglas Pharmaceuticals Limited, a key pharma product manufacturer headquartered in New Zealand, has signed a partnership deal with The University of Western Australia (UWA) & Telethon Kids Institute for developing new cancer immunotherapies. Reportedly, Dr. Joost Lesterhuis, a leading cancer researcher & group leader at the UWA, along with his team, has utilized network analysis procedure to study how genes are connected with one another in any cancer type and how they can be activated for responding favorably towards the cancer immunotherapy.

Apparently, the research group has concluded that the medicine combinations will help activate the genes, thereby acquiring positive outcomes post immunotherapy. The deal is expected to help the scientists at UWA develop such drug combinations in collaboration with Douglas Pharma, ultimately aiming toward a clinical trial by next year.

According to Dr. Joost, the alliance will generate a new opportunity for both the organizations to transform their research into clinical data that will assist in coining effective methods for cancer treatment. He has further stated that the association will help in performing vital lab studies and understand why some of the subjects respond positively to cancer immunotherapy while some others do not.

Jeff Douglas, the MD of Douglas Pharmaceuticals, is of the view that the strategic move will help in converting cancer research activities into the development of smart drugs for improving treatment in cancer patients that do not respond favorably to the existing therapies. Dr. Lesterhuis is of the view that the myriad approaches from unrelated fields such as cancer medicine, mathematics, and computer science can provide the researchers with unique insights into cancer treatments.

One of the researchers working under the auspices of Joost has remarked that the partnership will help in creating a new approach that can determine new as well as safe combinations of the authorized drugs that can benefit cancer subjects, thereby propelling its therapeutic uses across the cancer therapy sector.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...